文献速递瓣膜外科

美国Medicare人群中经股动脉与替代入路TAVR的结局、再入院与费用比较

Outcomes, readmissions, and costs in transfemoral and alterative access transcatheter aortic valve replacement in the US Medicare population.
PubMed 文献 · J Thorac Cardiovasc Surg · 2017-06-16

该研究基于2011至2012年Medicare按服务收费数据,比较经股动脉(TF)、经心尖(TA)和经主动脉(TAO)TAVR的结局与费用。TA和TAO患者30天死亡率高于TF(9.6%、8.0%对5.0%,P<.001),但1年后调整死亡率无差异。使用体外循环(CPB)与调整死亡率升高(HR 2.13,P<.01)及30天费用增加相关。

要点

  • TA和TAO患者30天死亡率高于TF患者,但1年后调整死亡率无差异。
  • TA患者更可能需要CPB,CPB与调整死亡率升高和费用增加相关。
  • TF的30天费用最低,TAO最高。

核心结论

  • 对于不适合TF TAVR的患者,TAO和TA入路提供相似的临床结局和相似费用,手术和1年生存可接受,但TA患者CPB使用率更高。
  • CPB与更差生存和更高费用相关。

研究设计与样本

  • 回顾性队列研究,使用2011年1月1日至2012年11月30日Medicare按服务收费索赔数据,纳入TF(n=4065)、TA(n=691)和TAO(n=274)TAVR患者。
  • 医院收费通过医院特定Medicare成本收费比转换为成本。

主要发现

  • TA和TAO患者较TF患者更可能为女性,并患有外周血管疾病、慢性肺病和肾衰竭。
  • 30天死亡率:TA 9.6%,TAO 8.0%,TF 5.0%(P<.001)。
  • 1年后调整死亡率按入路无差异。
  • TA患者更可能需要CPB。
  • 调整死亡率增加与CPB相关(风险比2.13;P<.01),并与30天费用增加相关($62,000 [IQR $45,100-$86,400] 对 $48,800 [IQR $38,100-$62,900];P<.01)。

临床怎么用

  • 在选择TAVR入路时,对于不适合TF的患者,TAO和TA是可接受的替代选择,但需注意TA患者CPB使用率较高。
  • CPB的使用与更差生存和更高费用相关,应优化患者选择以降低CPB需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To comprehensively evaluate and compare utilization, outcomes, and especially costs of transfemoral (TF), transapical (TA), and transaortic (TAO) transcatheter aortic valve replacement (TAVR). METHODS: All Medicare fee-for-service patients undergoing TF (n = 4065), TA (n = 691), or TAO (n = 274) TAVR between January 1, 2011, and November 30, 2012, were identified using Health Care Procedure Classification Codes present on Medicare claims. Hospital charges from Medicare claims were converted to costs using hospital-specific Medicare cost-to-charge ratios. RESULTS: TA and TAO patients were similar in age, race, and common comorbidities. Compared with TF patients, TA and TAO patients were more likely to be female and to have peripheral vascular disease, chronic lung disease, and renal failure. Thirty-day mortality rates were higher among TA and TAO patients than among TF patients (TA, 9.6%; TAO, 8.0%; TF, 5.0%; P < .001). Adjusted mortality beyond 1 year did not differ by access. TA patients were more likely to require cardiopulmonary bypass (CPB). Increased adjusted mortality was associated with CPB (hazard ratio, 2.13; P < .01) and increased 30-day cost ($62,000 [interquartile range (IQR)], $45,100-$86,400 versus $48,800 [IQR, $38,100-$62,900]; P < .01). Cost at 30 days was lowest for TF ($48,600) compared with TA ($49,800; P < .01) and TAO ($53,200; P = .03). CONCLUSIONS: For patients ineligible to receive TF TAVR, TAO and TA approaches offer similar clinical outcomes at similar cost with acceptable operative and 1-year survival, except for higher rates of CPB use in TA patients. CPB was associated with worse survival and increased costs.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. McCarthy FH, Spragan DD, Savino D, et al. Outcomes, readmissions, and costs in transfemoral and alterative access transcatheter aortic valve replacement in the US Medicare population. J Thorac Cardiovasc Surg. 2017. PMID: 28712578. doi:10.1016/j.jtcvs.2017.04.090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。